Magdalena K. Kaneva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Magdalena K. Kaneva has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Costantino Pitzalis
Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, and Barts NIHR Biomedical Research Centre & Barts Health NHS Trust, London, UK
2 shared publications - Francesco Dell'ACcio
Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
2 shared publications - Mauro Perretti
Queen Mary University of London
2 shared publications - Adrian Moore
Centre for inflammation and therapeutic innovation, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom; UCB Pharma, Bath Road, Slough, United Kingdom
1 shared publication - Ahmed Ali
General Surgery Mid Yorkshire Hospitals NHS Foundation Trust Wakefield UK
1 shared publication - Aida Barawi
Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
1 shared publication
Latest Publications
- Open Access
- 27 September 2021
- Published by Wiley in The FEBS Journal
- Vol. 289 (1) , 113-116
Neutrophil elastase and its inhibitors—overlooked players in osteoarthritis
Cartilage homeostasis is maintained by a delicate balance between anabolism and catabolism. In osteoarthritis, pathological biomechanics or injury triggers cartilage breakdown, nonresolving synovial inflammation, and bone changes, causing reduced joint mobility and incapacitating pain. Undoubtedly, the most important cartilage degrading collagenase during osteoarthritis, matrix metalloproteinase (MMP)‐13, is activated by an unlikely player: neutrophil elastase. Although primarily associated with inflammatory arthritis, neutrophil elastase is present in the osteoarthritic joint, and through activating MMP‐13, spurs a cascade of events leading not just to the aberrant destruction of the cartilage itself, but to the proteolysis of its own inhibitor, alpha‐1‐antitrypsin, as described in the new study by Wilkinson et al. Endowed with potent chondrogenic and cartilage‐protective properties, the loss of alpha‐1‐antitrypsin from cartilage will have major consequences for osteoarthritis progression, and strategies to prevent its loss, or replace it, might provide an innovative treatment opportunity that should not be ignored.Comment on: https://doi.org/10.1111/febs.16127
- 27 September 2021
- Published by Wiley in The FEBS Journal
- Vol. 289 (1) , 113-116
Open AccessNeutrophil elastase and its inhibitors—overlooked players in osteoarthritis
Cartilage homeostasis is maintained by a delicate balance between anabolism and catabolism. In osteoarthritis, pathological biomechanics or injury triggers cartilage breakdown, nonresolving synovial inflammation, and bone changes, causing reduced joint mobility and incapacitating pain. Undoubtedly, the most important cartilage degrading collagenase during osteoarthritis, matrix metalloproteinase (MMP)‐13, is activated by an unlikely player: neutrophil elastase. Although primarily associated with inflammatory arthritis, neutrophil elastase is present in the osteoarthritic joint, and through activating MMP‐13, spurs a cascade of events leading not just to the aberrant destruction of the cartilage itself, but to the proteolysis of its own inhibitor, alpha‐1‐antitrypsin, as described in the new study by Wilkinson et al. Endowed with potent chondrogenic and cartilage‐protective properties, the loss of alpha‐1‐antitrypsin from cartilage will have major consequences for osteoarthritis progression, and strategies to prevent its loss, or replace it, might provide an innovative treatment opportunity that should not be ignored.Comment on: https://doi.org/10.1111/febs.16127
- Open Access
- 31 March 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (5) , e21472
Alpha‐1‐antitrypsin reduces inflammation and exerts chondroprotection in arthritis
While new treatments have been developed to control joint disease in rheumatoid arthritis, they are partially effective and do not promote structural repair of cartilage. Following an initial identification of α‐1‐Antitrypsin (AAT) during the resolution phase of acute inflammation, we report here the properties of this protein in the context of cartilage protection, joint inflammation, and associated pain behavior. Intra‐articular and systemic administration of AAT reversed joint inflammation, nociception, and cartilage degradation in the KBxN serum and neutrophil elastase models of arthritis. Ex vivo analyses of arthritic joints revealed that AAT promoted transcription of col2a1, acan, and sox9 and downregulated mmp13 and adamts5 gene expression. In vitro studies using human chondrocytes revealed that SERPINA1 transfection and rAAT protein promoted chondrogenic differentiation through activation of PKA‐dependent CREB signaling and inhibition of Wnt/β‐catenin pathways. Thus, AAT is endowed with anti‐inflammatory, analgesic, and chondroprotective properties that are partially inter‐related. We propose that AAT could be developed for new therapeutic strategies to reduce arthritic pain and repair damaged cartilage.
- 31 March 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (5) , e21472
Open AccessAlpha‐1‐antitrypsin reduces inflammation and exerts chondroprotection in arthritis
While new treatments have been developed to control joint disease in rheumatoid arthritis, they are partially effective and do not promote structural repair of cartilage. Following an initial identification of α‐1‐Antitrypsin (AAT) during the resolution phase of acute inflammation, we report here the properties of this protein in the context of cartilage protection, joint inflammation, and associated pain behavior. Intra‐articular and systemic administration of AAT reversed joint inflammation, nociception, and cartilage degradation in the KBxN serum and neutrophil elastase models of arthritis. Ex vivo analyses of arthritic joints revealed that AAT promoted transcription of col2a1, acan, and sox9 and downregulated mmp13 and adamts5 gene expression. In vitro studies using human chondrocytes revealed that SERPINA1 transfection and rAAT protein promoted chondrogenic differentiation through activation of PKA‐dependent CREB signaling and inhibition of Wnt/β‐catenin pathways. Thus, AAT is endowed with anti‐inflammatory, analgesic, and chondroprotective properties that are partially inter‐related. We propose that AAT could be developed for new therapeutic strategies to reduce arthritic pain and repair damaged cartilage.
- 2 September 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (559)
Agrin induces long-term osteochondral regeneration by supporting repair morphogenesis
Agrin heals joint surfaces by recruiting joint stem cells and inducing the formation of cartilage and bone with correct architecture in mice and sheep.
- 2 September 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (559)
Agrin induces long-term osteochondral regeneration by supporting repair morphogenesis
Agrin heals joint surfaces by recruiting joint stem cells and inducing the formation of cartilage and bone with correct architecture in mice and sheep.
- Open Access
- 1 April 2017
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 198 (7) , 2876-2885
Identification of Novel Chondroprotective Mediators in Resolving Inflammatory Exudates
We hypothesized that exudates collected at the beginning of the resolution phase of inflammation might be enriched for tissue protective molecules; thus an integrated cellular and molecular approach was applied to identify novel chondroprotective bioactions. Exudates were collected 6 h (inflammatory) and 24 h (resolving) following carrageenan-induced pleurisy in rats. The resolving exudate was subjected to gel filtration chromatography followed by proteomics, identifying 61 proteins. Fractions were added to C28/I2 chondrocytes, grown in micromasses, ions with or without IL-1β or osteoarthritic synovial fluids for 48 h. Three proteins were selected from the proteomic analysis, α1-antitrypsin (AAT), hemopexin (HX), and gelsolin (GSN), and tested against catabolic stimulation for their effects on glycosaminoglycan deposition as assessed by Alcian blue staining, and gene expression of key anabolic proteins by real-time PCR. In an in vivo model of inflammatory arthritis, cartilage integrity was determined histologically 48 h after intra-articular injection of AAT or GSN. The resolving exudate displayed protective activities on chondrocytes, using multiple readouts: these effects were retained in low m.w. fractions of the exudate (46.7% increase in glycosaminoglycan deposition; ∼20% upregulation of COL2A1 and aggrecan mRNA expression), which reversed the effect of IL-1β. Exogenous administration of HX, GSN, or AAT abrogated the effects of IL-1β and osteoarthritic synovial fluids on anabolic gene expression and increased glycosaminoglycan deposition. Intra-articular injection of AAT or GSN protected cartilage integrity in mice with inflammatory arthritis. In summary, the strategy for identification of novel chondroprotective activities in resolving exudates identified HX, GSN and AAT as potential leads for new drug discovery programs.
- 1 April 2017
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 198 (7) , 2876-2885
Open AccessIdentification of Novel Chondroprotective Mediators in Resolving Inflammatory Exudates
We hypothesized that exudates collected at the beginning of the resolution phase of inflammation might be enriched for tissue protective molecules; thus an integrated cellular and molecular approach was applied to identify novel chondroprotective bioactions. Exudates were collected 6 h (inflammatory) and 24 h (resolving) following carrageenan-induced pleurisy in rats. The resolving exudate was subjected to gel filtration chromatography followed by proteomics, identifying 61 proteins. Fractions were added to C28/I2 chondrocytes, grown in micromasses, ions with or without IL-1β or osteoarthritic synovial fluids for 48 h. Three proteins were selected from the proteomic analysis, α1-antitrypsin (AAT), hemopexin (HX), and gelsolin (GSN), and tested against catabolic stimulation for their effects on glycosaminoglycan deposition as assessed by Alcian blue staining, and gene expression of key anabolic proteins by real-time PCR. In an in vivo model of inflammatory arthritis, cartilage integrity was determined histologically 48 h after intra-articular injection of AAT or GSN. The resolving exudate displayed protective activities on chondrocytes, using multiple readouts: these effects were retained in low m.w. fractions of the exudate (46.7% increase in glycosaminoglycan deposition; ∼20% upregulation of COL2A1 and aggrecan mRNA expression), which reversed the effect of IL-1β. Exogenous administration of HX, GSN, or AAT abrogated the effects of IL-1β and osteoarthritic synovial fluids on anabolic gene expression and increased glycosaminoglycan deposition. Intra-articular injection of AAT or GSN protected cartilage integrity in mice with inflammatory arthritis. In summary, the strategy for identification of novel chondroprotective activities in resolving exudates identified HX, GSN and AAT as potential leads for new drug discovery programs.
- Open Access
- 1 November 2014
- Published by Elsevier in Biochemical Pharmacology
- Vol. 92 (2) , 336-347
Melanocortin peptides protect chondrocytes from mechanically induced cartilage injury
- 1 November 2014
- Published by Elsevier in Biochemical Pharmacology
- Vol. 92 (2) , 336-347
Open AccessMelanocortin peptides protect chondrocytes from mechanically induced cartilage injury